MAMeor Mohd Redzuan Meor Mohd Affandi

Meor Mohd Redzuan Meor Mohd Affandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meor Mohd Redzuan Meor Mohd Affandi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preparation and Characterization of Prednisolone-Loaded Solid Lipid Nanoparticles for Potential Transdermal Application

    by Sabrina Mohamed Hasnol, Meor Mohd Redzuan Meor Mohd Affandi, Wong Tin Wui, Nor Khaizan Anuar

    Introduction: Transdermal delivery of prednisolone using solid-lipid nanoparticles (SLN) offers a promising strategy to enhance drug administration by enabling direct transport through the skin into the systemic circulation. However, the impact of processing conditions on the physicochemical properties and release mechanisms of prednisolone‑loaded SLN remains insufficiently explored. Methods: The present study developed prednisolone-loaded SLN using an emulsification–homogenization– ultrasonication approach. Key process parameters, namely homogenization stirring speed and duration, as well as ultrasonication time, temperature, and power, were systematically refined based on particle size, polydispersity index (PDI), and zeta potential. The selected formulation was further characterized for entrapment efficiency (EE), drug loading (DL), attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and in vitro drug release. Results: The experimentally determined DL ranged from 8.52 ± 0.55 to 9.89 ± 1.73%, corresponding to 85-99% of the intended loading, indicating minimal processing loss. Formulation H3, selected for further characterization based on its physicochemical profile, was homogenized at 10,000 rpm for 4 minutes, followed by ultrasonication at 60°C and 60 W for 4 minutes. H3 exhibited a particle size of 319.00 ± 56.15 nm, a PDI of 0.48 ± 0.022, a zeta potential of −19.86 ± 9.56 mV, and an EE of 98.25 ± 0.49%. All formulations demonstrated sustained drug release over 24 h with no statistically significant differences observed among them (p = 0.148). Discussion: Kinetic modeling showed that both Higuchi and Korsmeyer–Peppas models adequately described the release profile of H3, suggesting heterogeneous release behavior involving overlapping diffusion- and matrix- related mechanisms. ATR-FTIR and DSC analyses indicated alterations in intermolecular interactions and lipid packing behavior following nanoparticle formation, while TEM confirmed spherical morphology and absence of visible aggregation, consistent with successful formation of the SLN system. conclusion: This study suggested prednisolone-loaded SLN as a potential transdermal drug delivery system, with sustained drug release profiles. Conclusion: Prednisolone-loaded SLN prepared using emulsification–homogenization–ultrasonication demonstrated favorable physicochemical properties and sustained release behavior governed by combined diffusion and matrix-related processes. Further studies on long-term stability, as well as ex vivo and in vivo skin permeation, are required to confirm their suitability for transdermal application.

  • Open Access

    Correction: Toxicological evaluation and mycochemical characterisation of aqueous extract of Schizophyllum commune

    by Zainul Amiruddin Zakaria, Mohammad Amil Zulhilmi Benjamin, Nur Liana Md Nasir, Hussin Muhammad, Lilis Sulistyorini, Roro Azizah, Gurmeet Kaur Surindar Singh, Meor Mohd Redzuan Meor Mohd Affandi, Nornazirah Azizan, Azmahani Abdullah, et al.

  • Open Access

    Toxicological evaluation and mycochemical characterisation of aqueous extract of Schizophyllum commune

    by Zainul Amiruddin Zakaria, Mohammad Amil Zulhilmi Benjamin, Nur Liana Md Nasir, Hussin Muhammad, Lilis Sulistyorini, Roro Azizah, Gurmeet Kaur Surindar Singh, Meor Mohd Redzuan Meor Mohd Affandi, Nornazirah Azizan, Azmahani Abdullah, et al.


  • Open Access

    Engineering Optimized Nanostructured Lipid Carriers for Astaxanthin: A Response Surface Methodology Approach

    by Nur Rafiqah Abdol Wahab, Meor Mohd Redzuan Meor Mohd Affandi, Sharida Fakurazi, Ekram Alias, Haniza Hassan

    Introduction: The xanthophyll carotenoid astaxanthin is well-known for its potent antioxidant properties, which are superior to those of other antioxidants such as vitamins C and E. However, this highly hydrophobic compound has low solubility and poor oral bioavailability, limiting its efficacy and clinical application. To address these pharmacokinetic challenges, nanostructured lipid carriers (NLC) have been proposed as potential lipid-based drug carriers for the oral delivery of astaxanthin owing to their excellent biocompatibility, stability, and efficient drug loading capacity. Purpose: In this study, we aimed to develop an NLC using cocoa butter and palm oil for astaxanthin encapsulation, and to optimize the nanoformulation by employing Response Surface Methodology (RSM), a statistical approach. Methods: Three-factor Central Composite Design (CCD) in RSM was used to understand the effect of independent variables on response variables. The size, polydispersity index, and encapsulation efficiency of the astaxanthin-loaded NLC were also characterized. Results: Findings of this study indicated that the mass of cocoa butter, palm oil and Tween 80 influenced the particle size, polydispersity index and zeta potential of NLC. The experimental determination of NLC did not differ significantly from the predicted RSM outcomes with size, polydispersity index and zeta potential of 254.42 ± 3.91 nm, 0.38 ± 0.01 and − 30.54 ± 0.85 mV, respectively. This nanoparticulate system showed an excellent astaxanthin entrapment efficiency of 99.69± 0.0003%. Conclusion: The ideal combination of each composition in the NLC formulation yielded nanoparticles with desirable particle size, polydispersity index, and zeta potential for efficient oral delivery of astaxanthin. Plain Language Summary: Astaxanthin is a natural antioxidant that is much stronger than vitamins C and E. However, it does not dissolve well in water and is poorly absorbed when administered orally, which limits its usefulness. To overcome this drawback, this study explored the use of nanostructured lipid carriers (NLC), which are tiny fat-based particles, to improve astaxanthin movement in the body. An NLC formulation was developed using cocoa butter and palm oil. The optimization process was conducted using a statistical method called Response Surface Methodology (RSM) to determine the best combination of ingredients. Different amounts of cocoa butter, palm oil, and a stabilizer (Tween 80) can affect the size, stability, and ability of the particles to hold astaxanthin. The results also showed that the optimized NLC had a small and uniform size (approximately 254 nm), stable dispersion (zeta potential of − 30.54 mV), and highly efficient astaxanthin trapping (99.69%). In conclusion, we successfully developed an NLC formulation that can efficiently carry astaxanthin, potentially improving its absorption and effectiveness when used as a supplement or medicine.


  • Exploring astaxanthin: a comprehensive review on its pharmacokinetics properties and neuroprotective potential

    by A. S. Mohd Shafie, S. N. Kamarudin, M. M. R. Meor Mohd Affandi, R. Siran

    Carotenoids are naturally occurring bio-pigments found in microalgae, plants, fungi, bacteria, and various aquatic animals. They are generally classified into carotenes and xanthophylls based on their structural features. Among them, astaxanthin-a xanthophyll carotenoid-has attracted increasing attention due to its potent antioxidant, anti-inflammatory, and anti-apoptotic properties, which contribute to a range of health benefits. This review highlights the structural features, physicochemical properties, pharmacokinetics, and therapeutic potential of astaxanthin, particularly focusing on its neuroprotective effects in neurological disorders. To provide a comprehensive overview, we systematically searched published articles across Scopus, Google Scholar, PubMed, and Medline databases from inception to January 1, 2025. Recent advancements in drug formulation and delivery technologies have enhanced astaxanthin's ability to cross the blood-brain barrier (BBB), significantly increasing its potential as a therapeutic agent for neurological diseases. With its multifaceted biological effects and growing evidence of neuroprotection, astaxanthin shows great promise in the treatment of neurological disorders, particularly stroke. These findings support its future development and application in pharmaceutical strategies aimed at brain health.